A Phase 1, Open-Label Study to Evaluate the Safety, Biodistribution, Imaging Characteristics, and Radiation Dosimetry of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
Latest Information Update: 09 Dec 2025
At a glance
- Drugs 18F LY 4214835 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eli Lilly and Company
Most Recent Events
- 09 Dec 2025 New trial record